Imugene advances to combination dosing in Phase 1 of its onCARlytics solid tumor trial.

Imugene advances to combination dosing in Phase 1 of its onCARlytics solid tumor trial, signifying progress in the cancer treatment research. This Australian biotech company continues to make strides in their ongoing clinical trial. Their focus on combination therapy could potentially enhance treatment outcomes for patients with solid tumors.